ISSN 2149-2263 | E-ISSN 2149-2271
pdf
Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin? [Anatol J Cardiol]
Anatol J Cardiol. 2007; 7(1): 54-58

Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?

Hatice Selçuk1, M. Timur Selçuk2, Orhan Maden2
1Türkiye Yüksek İhtisas Hastanesi, Kardiyoloji Kliniği Ankara, Türkiye
2Türkiye Yüksek İhtisas Hastanesi, Kardiyoloji Bölümü, Ankara, Türkiye

Nonvalvular atrial fibrillation is the most common cardiac arrhythmia associated with a substantial risk of thromboembolism and stroke. Despite numerous disadvantages that limit its efficacy and safety, warfarin is widely used in the prevention and treatment of thromboembolism related with atrial fibrillation. Ximelagatran, an oral direct thrombin inhibitor has the potential to be an alternative choice in the prevention and therapy of thromboembolism related with atrial fibrillation. Studies compared ximelagatran with warfarin in nonvalvular atrial fibrillation at risk for stroke showed that fixed dose oral ximelagatran is effective as adjusted dose warfarin in stroke prevention. Ximelagatran has numerous advantages over warfarin in clinical practice. Although it seems as a promising option for the prevention and therapy of thromboembolism, its safety and efficacy need to be determined definitely by further clinical trials.

Keywords: Atrial fibrillation, antithrombotic therapy, ximelagatran

Atriyal fibrilasyonda Ximelagatran ile antitrombotik tedavi: Ximelagatran warfarin’e alternatif olabilir mi?

Hatice Selçuk1, M. Timur Selçuk2, Orhan Maden2
1Türkiye Yüksek İhtisas Hastanesi, Kardiyoloji Kliniği Ankara, Türkiye
2Türkiye Yüksek İhtisas Hastanesi, Kardiyoloji Bölümü, Ankara, Türkiye

Anahtar Kelimeler: Atriyal fibrilasyon, antitrombotik tedavi, ximelagatran

Hatice Selçuk, M. Timur Selçuk, Orhan Maden. Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?. Anatol J Cardiol. 2007; 7(1): 54-58
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 The Anatolian Journal of Cardiology



Kare Publishing is a subsidiary of Kare Media.